SARS-CoV-2 Surrogate Virus Neutralisation Assay
Competitive Inhibition of ACE2 / RBD Interaction
Simultaneous detection of neutralising SARS-CoV-2 antibodies
Randox SARS-CoV-2 Surrogate Virus Neutralisation Assay qualitatively detects total neutralizing antibodies targeting the viral spike (S) protein receptor-binding domain (RBD) in an isotype- and species-independent manner.
Intended as an aid in the identification of patients with neutralising antibodies to the SARS-CoV-2 virus which infers protective immunity and will allow stratification of at-risk groups/populations where additional booster vaccinations may be required.
Utilising patented Biochip Array Technology on the Evidence Investigator, the assay measures circulating antibodies against SARS-CoV-2 that block interaction between the S (RBD) protein with the human angiotensin-converting enzyme 2 (ACE2) cell surface receptor. The test measures the binding capability of these two proteins in the presence of the patient’s serum or plasma to identify the presence of neutralising SARS-CoV-2 antibodies.
Cost effective and efficient semi-automated multiplex testing solution
Medium to high throughput (54 samples in < 3 hours)
Limited sample volume requirement (12ul)
Suitable for clinical and research testing
Comprehensive immunoassay and molecular test menu available
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page